Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | INCY Incyte | ABT Abbott Laboratories |
|---|---|---|
| Price | $124.75 +2.1% | $102.36 -0.7% |
| StockIQ Score | 62C+ Moderate Risk: Medium | 51C- Moderate Risk: Medium |
| Technical | 36F | 23F |
| Fundamental | 79B+ | 72B |
| Growth | 74B | 45D+ |
| Fair Value | 50C- | 38F |
| News | 98A+ | 92A+ |
| Quality | 58C | 63C+ |
| Risk | 56C | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Incyte outperforms Abbott Laboratories in nearly every category. Its investor score (71 vs. 54) and rating ("STRONG" vs. "MODERATE") are stronger. Incyte also leads in technical (72 vs. 50), fundamental (79 vs. 72), and growth scores (74 vs. 45), though Abbott has a slightly better valuation score (unavailable for Incyte).